PURPOSE: To assess the occurrence of high-risk epithelial lesions in women of breast cancer families with and without a BRCA mutation. PATIENTS AND METHODS: Prospective study of women at very high risk of breast cancer undergoing prophylactic mastectomy (68 BRCA1 mutation carriers, 14 BRCA2 mutation carriers and 24 non-BRCA mutation carriers). RESULTS: The prevalence of high-risk lesions is equal in women with a BRCA1 or a BRCA2 mutation, but is higher in non-BRCA mutation carriers: all lesions 43% versus 71% (p=0.02), atypical lobular hyperplasia 26% versus 67% (p=0.001), atypical ductal hyperplasia 17% versus 42% (p=0.01), lobular carcinoma-in situ 15% versus 29% (p=0.10) and ductal carcinoma-in situ 9% versus 17% (p=0.25). The presence of high-risk lesions is related to absence of a BRCA mutation and to age over 40 years. CONCLUSION: Women with an autosomal dominant family history for breast cancer, with and without a BRCA mutation are prone to develop high-risk epithelial lesions, especially over 40 years.
PURPOSE: To assess the occurrence of high-risk epithelial lesions in women of breast cancer families with and without a BRCA mutation. PATIENTS AND METHODS: Prospective study of women at very high risk of breast cancer undergoing prophylactic mastectomy (68 BRCA1 mutation carriers, 14 BRCA2 mutation carriers and 24 non-BRCA mutation carriers). RESULTS: The prevalence of high-risk lesions is equal in women with a BRCA1 or a BRCA2 mutation, but is higher in non-BRCA mutation carriers: all lesions 43% versus 71% (p=0.02), atypical lobular hyperplasia 26% versus 67% (p=0.001), atypical ductal hyperplasia 17% versus 42% (p=0.01), lobular carcinoma-in situ 15% versus 29% (p=0.10) and ductal carcinoma-in situ 9% versus 17% (p=0.25). The presence of high-risk lesions is related to absence of a BRCA mutation and to age over 40 years. CONCLUSION:Women with an autosomal dominant family history for breast cancer, with and without a BRCA mutation are prone to develop high-risk epithelial lesions, especially over 40 years.
Authors: Regina Kroiss; V Winkler; K Kalteis; D Bikas; M Rudas; M Tea; C Fuerhauser; D Muhr; H Cerny; S Glueck; E Petru; H Concin; E Kubista; P Oefner; T Wagner Journal: J Cancer Res Clin Oncol Date: 2008-04-08 Impact factor: 4.553
Authors: Banu Arun; Kristen J Vogel; Adriana Lopez; Mike Hernandez; Deann Atchley; Kristine R Broglio; Christopher I Amos; Funda Meric-Bernstam; Henry Kuerer; Gabriel N Hortobagyi; Constance T Albarracin Journal: Cancer Prev Res (Phila) Date: 2009-01-27
Authors: Robert M W Hofstra; Amanda B Spurdle; Diana Eccles; William D Foulkes; Niels de Wind; Nicoline Hoogerbrugge; Frans B L Hogervorst Journal: Hum Mutat Date: 2008-11 Impact factor: 4.878
Authors: Laura N Burga; Nadine M Tung; Susan L Troyan; Mihnea Bostina; Panagiotis A Konstantinopoulos; Helena Fountzilas; Dimitrios Spentzos; Alexander Miron; Yosuf A Yassin; Bernard T Lee; Gerburg M Wulf Journal: Cancer Res Date: 2009-02-03 Impact factor: 12.701
Authors: Petra van der Groep; Paul J van Diest; Yvonne H C M Smolders; Margreet G E M Ausems; Rob B van der Luijt; Fred H Menko; Joost Bart; Elisabeth G E de Vries; Elsken van der Wall Journal: PLoS One Date: 2013-02-08 Impact factor: 3.240
Authors: Rachel L Yang; Rosemarie Mick; Kathreen Lee; Holly L Graves; Katherine L Nathanson; Susan M Domchek; Rachel R Kelz; Paul J Zhang; Brian J Czerniecki Journal: J Transl Med Date: 2015-10-24 Impact factor: 5.531